EastPharma Ltd was established in 2006 with the aim of becoming a major player in the fast growing emerging markets pharmaceutical industry by means of organic growth, acquisitions and consolidation in fragmented markets. EastPharma Ltd conducted an IPO and became a London Stock Exchange (LSE) listed company in 2008. The first major undertaking of EastPharma Ltd was to facilitate the implementation of DEVA’s new growth strategy, a leading Turkish generic pharmaceuticals company. In 2006, EastPharma indirectly became DEVA’s majority shareholder and installed a new management team. The company is headquarter in Istanbul, Turkey, manufactures and sells pharmaceutical generics, formulations and active pharmaceutical ingredients (APIs), and it is one of the leading pharmaceutical companies in Turkey. EastPharma currently indirectly holds 82,21% of DEVA shares. Since EastPharma Ltd through EastPharma Sarl indirectly acquired control of the Turkish generic pharmaceutical company DEVA, it has applied experienced management expertise to ensure these subsidiaries are in a strong position to increase their market share and profitability.
Active since 1958, DEVA Holding has concentrated its efforts on increasing human health and quality of life. DEVA Holding has been operating in healthcare industry as one of Turkey’s long-standing pharmaceuticals producers with approximately 2200 employees, 3 production sites and awarded R&D centre.
With its EU GMP&US FDA approved production sites, its laboratories equipped with state-of-the-art technology and its strong team, DEVA Holding has annual production capacity of 515 million units. The company has approximately 600 product approvals in nearly 60 countries and exports medicine and pharmaceutical raw materials to more than 40 countries. In 2016 Devatis GmbH was established in Germany and started its operations by many attended and awarded tenders. In 2017, the US affiliate, Devatis Inc.is established with increasing momentum of the operations in that market and two products were exported to the USA.
The Swiss affiliate Devatis AG has been registered and became operational.
DEVATIS AG is initiating DEVA’s 60 years successful experience into Swiss Pharmaceutical Generic Market for the benefit of Swiss patients with the leadership of it’s Swiss Chairman of BOD and CEO Mr. Philipp Haas.
Currently, the portfolio of Devatis AG consists of hematology and oncology products and is still growing into other therapeutic areas such as CNS, systematic hormonal preparations and antiinfectives for systemic use.
Chairman of the Board of Directors
Chairman of the Board of Directors and CEO of DEVA Holding, Philipp Haas took MBA degree in the specialty of banking at St. Gallen Economy, Law and Business Administration University.
He was born in Switzerland. He speaks German, English, French, Spanish, Portuguese, Italian and Turkish fluently. Having served as investment consultant and director since 1992, Philipp Haas has a broad experience in markets of Eastern European Countries and particularly Turkish market. Having taken part in many restructuring projects in Ukraine and Turkey, Philipp Haas performed membership of many boards of directors on behalf of foreign corporate investors in 90s, among which are Rogan Brewery in Ukraine and Net Holding in Turkey. Having a broad experience in pharmaceutical industry, Philipp Haas served as consultant to funds in pharmaceutical industry in developing markets and oriented their investments to Eastern Europe. Among such firms is Slovakopharma named afterwards as Zentiva. Being the Chairman of the Board of Directors of EastPharma Ltd and DEVA Holding, Haas also serves as the Chairman of BOD in, Saba İlaç Sanayi ve Ticaret A.Ş, New Life Yaşam Sigorta A.Ş., EastPharma İlaç Üretim Pazarlama San. ve Tic. A.Ş., and member of BOD in EastPharma S.a.r.l. He also serves as a director in, Devatis Limited, Devatis Gmbh, Devatis A.G and Devatis Inc. Philipp Haas is the vice-president of the Pharmaceutical Industry Association of Turkey.